ECE2024 Poster Presentations Pituitary and Neuroendocrinology (120 abstracts)
Epidemiology of hypothalamic obesity in craniopharyngioma and other rare sellar and suprasellar tumors
Julian Witte 1 , Bastian Surmann 1 , Manuel Batram 1 , Markus Weinert 1 , Mathias Flume 2 , Nicolas Touchot 3 , Julia Beckhaus 4,5 , Carsten Friedrich 4 & Hermann Müller 4
1Vandage GmbH, Bielefeld, Germany; 2Gene Access GmbH, Dortmund, Germany; 3Rhythm Pharmaceuticals, Boston MA, United States; 4University Children’s Hospital, Carl von Ossietzky University Oldenburg, Klinikum Oldenburg AöR, Department of Pediatrics and Pediatric Hematology / Oncology, Oldenburg, Germany; 5Carl von Ossietzky University Oldenburg, Division of Epidemiology and Biometry, Oldenburg, Germany
Background: Hypothalamic obesity (HO) is defined as abnormal weight gain resulting in severe persistent obesity due to physical, tumor- and/or treatment related damage of the hypothalamus. The HO epidemiology is poorly understood. We developed a database algorithm supporting the standardized identification of tumor/treatment-related HO (TTR-HO) patients.
Methods: The algorithm is used to estimate incidence rates of TTR-HO patients in the German healthcare context from a representative claims database (n=5.42 million) covering 2010-2020. Patients were identified based on surgery/radiotherapy procedures and HO-associated tumor diagnoses (n=3,976). TTR-HO was defined by incident obesity and validated based on incident diabetes insipidus diagnosis and desmopressin prescription within a twelve-month period after surgery/radiotherapy. Uncertainty due to algorithm definitions is explored in sensitivity analyses.
Results: Estimated annual incidence of TTR-HO in Germany is between 0.7 and 1.7 cases per 1,000,000 persons (2019 prevalence: n=1,262 patients). With observed cases in all age groups, two HO-incidence peaks are identified: children/young adults aged 10-14 years and adults aged 40-44 years. Most frequent HO-validated tumor diagnoses are benign sellar/suprasellar tumors (6.1/1,000,000 persons over nine-years), including tumors of the craniopharyngeal duct (3.1/1,000,000), neoplasms of the pituitary gland (4.1/1,000,000), and nonspecific brain tumors of endocrine glands (2.4/1,000,000).
Conclusion: This is the first real-world database analysis of TTR-HO epidemiology, refining current estimates of HO-epidemiology and early patient identification. A more comprehensive characterization of HO patients, along with a better understanding of its clinical implications, will be crucial in developing optimal treatment strategies to improve patient outcomes.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more